Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, has announced it will release its second quarter 2024 financial results on Tuesday, August 13, 2024, before the market opens. The company will host a live webcast at 8am EDT on the same day to discuss the results.
Investors and interested parties can access the webcast through a registration link or via the Events & Presentations page on the company's website. A replay of the webcast will be available on Praxis' website for 90 days following the event. This announcement provides an opportunity for stakeholders to gain insights into the company's financial performance and operational progress in developing treatments for CNS disorders characterized by neuronal excitation-inhibition imbalance.
Praxis Precision Medicines (NASDAQ: PRAX), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per i disegni del sistema nervoso centrale (CNS), ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 martedì 13 agosto 2024, prima dell'apertura del mercato. L'azienda ospiterà un webcast in diretta alle 8:00 EDT lo stesso giorno per discutere i risultati.
Gli investitori e le parti interessate possono accedere al webcast tramite un link di registrazione o sulla pagina Eventi e Presentazioni del sito web dell'azienda. Una registrazione del webcast sarà disponibile sul sito di Praxis per 90 giorni dopo l'evento. Questo annuncio offre un'opportunità agli stakeholder per acquisire informazioni sulle performance finanziarie dell'azienda e sui progressi operativi nello sviluppo di trattamenti per i disturbi CNS caratterizzati da un'impareggiata eccitazione-inibizione neuronale.
Praxis Precision Medicines (NASDAQ: PRAX), una empresa biofarmacéutica en etapa clínica centrada en desarrollar terapias para trastornos del sistema nervioso central (CNS), ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el martes 13 de agosto de 2024, antes de la apertura del mercado. La empresa llevará a cabo un webcast en vivo a las 8:00 EDT el mismo día para discutir los resultados.
Los inversores y partes interesadas pueden acceder al webcast a través de un enlace de registro o en la página de Eventos y Presentaciones en el sitio web de la empresa. Una repetición del webcast estará disponible en el sitio de Praxis durante 90 días después del evento. Este anuncio ofrece a los interesados la oportunidad de obtener información sobre el desempeño financiero de la empresa y el progreso operativo en el desarrollo de tratamientos para los trastornos del CNS caracterizados por un desequilibrio entre excitación e inhibición neuronal.
프락시스 프리시전 메디슨스 (NASDAQ: PRAX)는 중추신경계(CNS) 장애를 위한 치료법 개발에 주력하는 임상 단계의 생물의약품 회사로, 2024년 2분기 재무 결과를 2024년 8월 13일 화요일에 시장 개장 전에 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시 EDT에 결과를 논의하기 위한 실시간 웹캐스트를 개최합니다.
투자자 및 이해관계자는 회사 웹사이트의 이벤트 및 프레젠테이션 페이지를 통해 등록 링크를 통해 웹캐스트에 접속할 수 있습니다. 웹캐스트의 재생은 이벤트 후 90일 동안 프락시스 웹사이트에서 제공됩니다. 이번 발표는 이해관계자에게 회사의 재무 성과 및 신경 세포의 흥분-억제 불균형으로 특징지어지는 CNS 장애에 대한 치료법 개발의 운영 진행 상황에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Praxis Precision Medicines (NASDAQ: PRAX), une entreprise bio-pharmaceutique en phase clinique axée sur le développement de thérapies pour les troubles du système nerveux central (SNC), a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le mardi 13 août 2024, avant l'ouverture du marché. L'entreprise organisera un webinaire en direct à 8h00 EDT le même jour pour discuter des résultats.
Les investisseurs et parties intéressées peuvent accéder au webinaire via un lien d'inscription ou via la page Événements & Présentations sur le site de l'entreprise. Un replay du webinaire sera disponible sur le site de Praxis pendant 90 jours suivant l'événement. Cette annonce offre aux parties prenantes l'opportunité d'acquérir des informations sur les performances financières de l'entreprise et les progrès opérationnels dans le développement de traitements pour les troubles du SNC caractérisés par un déséquilibre entre excitation et inhibition neuronale.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von Therapien für zentralnervöse Erkrankungen (ZNS) konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am Dienstag, den 13. August 2024, vor Markteröffnung veröffentlichen wird. Das Unternehmen wird am selben Tag um 8 Uhr EDT einen Live-Webcast veranstalten, um die Ergebnisse zu erörtern.
Investoren und Interessierte können über einen Registrierungslink oder die Seite Veranstaltungen & Präsentationen auf der Unternehmenswebsite auf den Webcast zugreifen. Eine Wiederholung des Webcasts wird 90 Tage nach der Veranstaltung auf der Website von Praxis verfügbar sein. Diese Ankündigung bietet den Stakeholdern die Möglichkeit, Einblicke in die finanzielle Leistung des Unternehmens und die betrieblichen Fortschritte bei der Entwicklung von Behandlungen für ZNS-Erkrankungen, die durch ein Ungleichgewicht zwischen neuronaler Erregung und Hemmung gekennzeichnet sind, zu gewinnen.
- None.
- None.
BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the second quarter ended June 30, 2024, before the financial markets open on Tuesday, August 13, 2024.
The Company will host a live webcast the same morning at 8am EDT, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
When will Praxis Precision Medicines (PRAX) release its Q2 2024 financial results?
How can investors access Praxis Precision Medicines' (PRAX) Q2 2024 earnings call?
Will there be a replay available for Praxis Precision Medicines' (PRAX) Q2 2024 earnings call?
What is the main focus of Praxis Precision Medicines (PRAX)?
